-

Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs Worldwide

Multiomics platform streamlines workflows and provides real-time insights, optimizing resource usage and ensuring smooth, data-driven operations

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--Tecan, the global leader in laboratory automation, today announced the unveiling of Veya™, a transformative liquid handling platform designed to bring efficiency, precision and compliance to laboratories of all sizes. The platform, showcased at the Society for Laboratory Automation and Screening (SLAS) international conference, San Diego, underscores Tecan’s continued commitment to innovation and the democratization of lab automation.

Veya overcomes key barriers in lab automation by offering an accessible and versatile platform that streamlines complex workflows and enables data-driven decision-making, while reducing downtime and enhancing productivity.

Veya combines AI-enhanced automation, prebuilt workflows and an intuitive analytics interface, OneView™, to simplify complex tasks, including multiomics workflows. Its seamless integration with existing systems enables laboratories to boost productivity and meet important regulatory standards, including Europe’s CE-IVD and IVDR requirements.

“Innovation at its best expands possibilities and redefines boundaries in life science research and diagnostics, opening the door to greater progress," said Mukta Acharya, Head of the Life Sciences Business division at Tecan. “Aligned with Tecan's purpose to scale healthcare innovation, Veya delivers cutting-edge technology that’s intuitive, scalable and extremely versatile. Its real-time data delivery, via a user-friendly interface, improves decision making, minimizes interruptions and frees up users to focus on their research.”

Key features of Veya:

- Simplified automation: Predeveloped workflows, intelligent analytics and a modular design boost productivity while reducing errors. Users report improvements of more than 60% in instrument utilization.
- High precision: Equipped with patented Air Restriction Pipetting (ARP), Veya handles volumes from 1 µl to 5 ml with precision.
- Real-time data: Improves decision-making and process optimization with live monitoring and actionable insights via a user-friendly interface.
- Continuous support: Features include 24-hour remote diagnostics, remote-guided troubleshooting and tailored service packages to minimize unplanned interruptions.
- Regulatory compliance: Veya is ideal for labs in regulated environments, ensuring compliance with key industry standards and regulatory requirements.

Veya reflects Tecan’s commitment to democratize automation for laboratories of all sizes, including those constrained by budget or resources. By providing scalable, versatile and intuitive solutions for the ever-evolving needs of scientific research and diagnostics, Tecan continues to scale healthcare innovation globally.

Visitors to SLAS2025 can visit Tecan’s booth #943 in San Diego or join the Veya unveiling event online, accessible at www.tecan.com/veya.

Contacts

Media contact:
Dr Ben Rutter
Zyme Communications
Tel: +44 (0) 7920 770 935
Email: ben.rutter@zymecommunications.com

Tecan

SWX:TECN

Release Versions

Contacts

Media contact:
Dr Ben Rutter
Zyme Communications
Tel: +44 (0) 7920 770 935
Email: ben.rutter@zymecommunications.com

Social Media Profiles
More News From Tecan

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

DURHAM, N.C. & MÄNNEDORF, Switzerland--(BUSINESS WIRE)--BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™, provided by Tecan. The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomi...

IBL International collaborates with Grifols on advanced biomarker panels

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market. Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single molecule coun...

Tecan Expands Portfolio for Specialty Diagnostics With an Asset Purchase Relating to Certain ELISA Kits

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--Tecan Group (SIX Swiss Exchange: TECN) today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics company, Revvity Inc. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. To ensure uni...
Back to Newsroom